Stockscreener 앱 받기
20.72
1.97%
0.40
시간 외 거래:
20.55
-0.17
-0.82%
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure - MSN
Mizuho upgrades ACADIA Pharmaceuticals (ACAD) - MSN
Oppenheimer maintains a balanced outlook on ACADIA Pharmaceuticals Inc. (ACAD) for 2026 - MSN
Wolfe Research notes conviction-driven opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) therapeutic domains - MSN
ACADIA Pharmaceuticals invites engagement at major pediatric event - Traders Union
ACADIA Pharmaceuticals Inc. (ACAD) Latest Stock News & Headlines - Yahoo Finance
ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year - Yahoo Finance
ACADIA Pharmaceuticals at Stifel CNS Forum: Strategic Insights Unveiled - Investing.com India
ACADIA Pharmaceuticals at Stifel CNS Forum: Strategic Insights Unveiled By Investing.com - Investing.com Canada
Algert Global LLC Has $8.54 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
(ACAD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ACADIA Pharmaceuticals (ACAD) Is Down 5.3% After EMA Rejects Trofinetide In Rett ReviewWhat's Changed - simplywall.st
Acadia Pharmaceuticals annual revenue surpasses 1 billion dollars at Nasdaq bell ceremony - Traders Union
Acadia Pharmaceuticals Rings the Opening Bell - Nasdaq
Acadia Pharmaceuticals Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Fred Alger Management LLC Sells 820,421 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness - Yahoo Finance
Braidwell LP Makes New $50.76 Million Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals confirms role at Stifel 2026 Virtual CNS Forum - Traders Union
Has ACADIA Pharmaceuticals (ACAD) Pullback Opened A New Opportunity For Investors? - simplywall.st
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors By Investing.com - Investing.com Nigeria
ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by First Trust Advisors LP - MarketBeat
ACADIA Pharmaceuticals unveils new Rett Syndrome research at Baltimore genetics meeting - Traders Union
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - The AI Journal
Acadia Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Growth and Innovations - Investing.com India
ACADIA Pharmaceuticals Showcases $1B+ Net Sales, $800M Cash, and Key Alzheimer’s Readout Ahead - MarketBeat
Equity grants for ACADIA (ACAD) principal accounting officer - Stock Titan
Acadia (ACAD) CFO receives new stock options and RSU awards - Stock Titan
ACADIA (NASDAQ: ACAD) awards options and RSUs to Chief Commercial Officer - Stock Titan
Acadia (NASDAQ: ACAD) EVP awarded large stock option and RSU grants - Stock Titan
Acadia Pharmaceuticals (ACAD) grants CEO large options and RSUs - Stock Titan
ACADIA Pharmaceuticals to exhibit at ACMG event in Baltimore - Traders Union
ACADIA Pharmaceuticals (ACAD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
ACAD plans re-examination after CHMP rejects Rett syndrome drug in EU (revised) - MSN
Neo Ivy Capital Management Buys Shares of 62,568 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (ACAD) Valuation After CHMP Setback On Trofinetide For Rett Syndrome - Sahm
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee - The Globe and Mail
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors - Investing.com India
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) - Finviz
ACADIA Pharmaceuticals Inc. $ACAD Stock Position Raised by Fisher Asset Management LLC - MarketBeat
Acadia Faces EU Setback On Trofinetide As Valuation Signals Diverge - Yahoo Finance
Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness? - Yahoo Finance
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU - The Globe and Mail
JP Morgan Raises Price Target for ACADIA Pharmaceuticals (ACAD) to $34 | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
CHMP Setback Puts Acadia Rett Plans And Revenue Outlook In Focus - simplywall.st
ACAD Announces New Review Following CHMP’s Decision Against Rett Syndrome Medication in Europe - Bitget
Rafferty Asset Management LLC Boosts Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors - BioSpace
ACADIA (ACAD) -7.1%: EU Agency Rejects Rett Syndrome Drug - Trefis
Acadia Pharmaceuticals appoints Jonathan M. Poole to its board of directors - marketscreener.com
Acadia Pharmaceuticals Appoints Jonathan M. Poole To Its Board Of Directors - TradingView
ACADIA Stock (-7.1%): EU Regulator Rejects Rett Syndrome Drug Trofinetide - Trefis
Acadia, undaunted by recent EU rejection, seeks CHMP re-examination of Rett syndrome med Daybue - Fierce Pharma
1.20%
0.06%
자본화:
|
볼륨(24시간):